INTRODUCTION {#Sec1}
============

Sex differences in human disease are usually attributed to sex specific life experiences, and sex hormones that influence the function of susceptible genes throughout the genome.^[@CR1]--[@CR5]^ Such factors do account for some dissimilarities. However, a major cause of sex-determined expression of disease has to do with differences in how males and females transcribe their gene-rich human X chromosomes, which is often underappreciated as a cause of sex differences in disease.^[@CR6]^ Males are the usual ones affected by X-linked pathogenic variants.^[@CR6]^ Females are biologically superior; a female usually has no disease, or much less severe disease than the male with the same variant, unless she is homozygous for the deleterious allele, or it is lethal for males.

The X chromosome carries 867 known protein coding genes.^[@CR7]^ Clearly, pathogenic variants that induce complete loss of function may be lethal to fetuses of both sexes; however, a number of these pathogenic variants---less severe, or occurring in less-essential genes---cause at least 533 X-linked diseases^[@CR8]^ that affect males more severely.^[@CR8]^ Rather than influencing sexual development, most of these genes play a role in nonreproductive human tissues, including brain, bone, blood, ears, heart, liver, kidney, retina, skin, and teeth.

Table [1](#Tab1){ref-type="table"} provides data about a substantial number of X-linked disorders obtained in large part from OMIM^[@CR8]^ that confirm the lesser susceptibility of females. The table is not all-inclusive, but it provides enough data to show the greater severity of these diseases in males, and to illustrate why some, but not all, females with the same X-linked deleterious allele are protected from its effects. This paper is motivated by the question: When so many women are protected from manifesting severe X-linked diseases, why are some of them susceptible?Table. 1Effect of X-inactivation (XI) on phenotype and cell selection in X-linked disorders.X-linked diseaseX MapGeneOMIMPhenotype: malesPhenotype: femalesCell selectionTissueXI skewing assay**Aarskog--Scott syndromeallelic with XLMR 16Xp11.254,445,453*FGD1*premature termination;truncation**305400Faciogenital dysplasia (ocular hypertelorism, shawl scrotum) with attention deficit hyperactivity, also XLIDSubtle features as widows peak or short statureSkewing toward mutant increases severity (i.e., translocation)ND**XLMR 16Xp11.2254,445,453*FGD1*missense**305400ID onlyNo affected femalesND**Acrogigantism X-LAGallelic with X-linked immunodeficiency with hyper IGMXq26.3136,648,176*CD40LG***300386**microduplication**300942Microduplications: only mosaic males are cited, so may be lethal in most males; mosaic males have acrogigantism, but no immunodeficiencyFemales are like mosaic males; acrogiantism, but no immunodeficiencyElevated growth hormone & prolactinMicroduplications have random XIAffected females may not be skewed until older ageLymphocytes*AR***Immunodeficiency with hyper IGM (HIGM) Immunodeficiency 3Xq26.3136,648,176*CD40LG*** **(CD40 ligand on T cells)variants**308230Decreased IgG, IgA, & IgE; susceptibility to opportunistic bacterial diseases, leading to liver disease; most have severe infections & shortened life spansHeterozygotes have normal levels of IgG, IgA, IgM, & IgENot convincing as reports conflict; it seems that half normal is enough to protect femalesT and B cells & fibroblastsAdrenoleukodystrophyXq28153,724,850*ABCD1*300100Demyelinization of brain, spinal cord, & adrenals. Often death in first decadeAdrenomyeloneuropathy; spastic paraplegia with ageYes, gradual. Favors mutant alleleWBC, RBC, skin fibroblasts clones*G6PD* & fatty acidsAlport syndromeXq22.3108,439,837*COL4A5*301050End stage renal disease; hearing loss; ocular malformationsMilder renal diseaseSeverity related to skewingSeverity related to skewing toward mutant alleleWBCKidney glomeruli*HPRT* & *PGK.COL45A* ImmunolabelAmelogenesis imperfectaXp22.211,293,412*AMELX*301200Hypoplastic amelogenesis imperfecta;Mottled teeth (fluoride independent); Homogeneous pattern of abnormalityAMELY expressed at 10% activity of AMELXVertically grooved teeth; variable depending on skew of XIOne homozygous female was affected like her hemizygous father, and more severe than her heterozygous mother; mother 25% skewed toward mutant, reflected in degree of groovingWBC*AR***Androgen insensitivityXq1267,544,020ARloss of function hypomorphic**300068Feminization or hypospadias and micropenisNo affected femalesNDNot severe (two clonal populations, but lower binding in heterozygotes)Skin fibroblast clones, both normal and mutant presentAndrogen binding**Kennedy spinal bulbar & muscular atrophyXq1267,544,020ARtrinucleotide repeat expansion**31320036--62 repeats in males; onset: 3rd--5th decade;slowly progressive muscle atrophy; progressive decrease in sperm productionAffected, if homozygous, but less affected because of higher androgens in males; heterozygotes usually normal, but some muscle crampsND**ATRX syndromeɑ-thalessemia/ID syndromeXq21.177,504,877*ATRX*300032**301040ID, thalassemia,genital abnormalities attributable to variants in PHD domainHemoglobin H inclusionsMild retardation, usually unaffectedYes, severe toward wild type alleleWBC, buccal smear*AR*ɑ**-thalessemia Myelodysplastic syndromeXq21.177,504,877*ATRX***300448Severe variant reducing activity to 3--4% normalNo affected femalesYes, severe toward wild type alleleWBC*AR***MR-hypotonic facies syndromeXq21.177,504,877*ATRX***309580Not so severe variants or those in the helical domainNo genital abnormalitiesNo affected femalesYes, severe toward wild type alleleWBC*AR*Barth syndromeXq28154,411,517*TAZ*302060Idiopathic cardiomyopathyMethylglutaconicaciduriaAbnormal mitochondriaDeath in childhoodNo affected femalesYes, severe toward wild type alleleWBC, fibroblasts*AR* in obligate heterozygotesBorjeson--Forssman--Lehmann syndromeXq26.2-3134,373,311*PHF6*301900ID, obesity, hypogonadism, epilepsy,facial dysmorphismMild ID11 females with de novo variants have Coffin--Siris phenotype all skewed 100% toward mutant allele, female with 70% skewing had milder symptomsYes, severe toward wild type alleleIf unskewed, then manifesting at least a littleIf skewed severely toward mutant, then severe diseaseWBC*FMR1, AR PGK1*Bruton agammaglobulinemiaXq22.1101,349,446*BTK*300300B-cell deficiency; boys lack circulating B cells;they are overcome by bacterial infectionsNo affected femalesYes, severe \>95%B cells*AR***Cataract 40Allelic with Nance--Horan syndromeXp22.1-22.217, 375,199*NHS*Lack of NHS leads to NH syndrome; milder variants give cataracts**302200Congenital cataracts with severe visual impairment & microcorneaAssociated with triplication of the locusNormal vision but develop cataracts in their 40sND**Nance--Horan SyndromeXp2217, 375,199*NHS***302350Congenital cataract leading to profound vision loss; dysmorphic features and malformed teeth Microcornea, microphthalmia, and mild or moderate IDSlightly reduced visionNDCharcot--Marie--ToothCMTX1Xq13.171,215,211*GJB1*302800304040Sensory & peripheral neuropathiesMilderNoWBC*AR***Charcot--Marie--ToothCMTX5Allelic with DFNX1& PRPS1 related goutXq22.3107,628,423*PRPS1***311070Optic atrophy, polyneuropathy, & deafnessMilderNo skewing determines severityWBC*AR*Charcot--Marie--ToothCMTX6Xp22.1124,465,226*PDK3*3009051 three-generation familyMales more severe than femalesFoot deformities, abnormal gait muscle weakness, sensory abnormalitiesSubtle features such as hand tremor with ageNDChristianson syndromeXq26.3135,974,595*SLC9A6* (*NHE6*)300231Profound ID; mute; developmental regression; impaired ocular movementsEpilepsy; microcephaly; cerebellar and brain stem atrophyMilderPsychiatric disordersStudy of 20 female heterozygotes shows deficit in at least one neurocognitive domain (ID 20%, learning differences 31%, speech delays 30%, & ADHD 20%); atypical parkinsonism, with ageND**CHILD syndromeXq28152 830, 966*NSDHL*loss of functionmissense & nonsense**308050Fetal lethalHemidysplasia with Unilateral ichthyosisYes, (in mice)Brain, skin, liver of *Bare Patches* mice*NSDHL* activity**CK syndromeAnalogous to bare patches in miceAllelic with CHILD syndromeXq28152 830, 966*NSDHL*300275hypomorphic variant**300831ID plus neonatal seizuresOnly males affected;Defect in cholesterol synthesisHeterozygotes not affectedNDChondrodysplasia punctata 1Xp22.232,934,631*ARSE*sometime small chromosomal deletions302950ID, bone defects;short stature;epiphyseal stipplingMilder symptomsNoMild cases not affectedWBC & fetal tissues*AR***Chondrodysplasia punctata 2(Conradi--Hunermann syndrome) CDPX2Allelic with Mend syndromeXp11.2348,521,807*EPB*Emopamil binding protein**302960Fetal lethal;Facial skin and skeletal dysplasiaOnly mosaic males surviveBilateral ichthyosisShort statureEpiphyseal stipplingHair and skin defectsOccasionally severe due to skewed XINoWBC*AR***Conradi--Hunermann--Happle syndrome CDPX2Xp11.2348,521,807*EBP***302960Mosaic grandfather (50%)Short statureMother: short stature;Mosaic skin defectFetus: severe bone abnormalities; no skin rashRandom XI in blood of both fetus & mother (not shown)Perhaps skewed in affected tissuesWBC*AR* splicing pathogenic variant in EBP causing extreme familial variability**MEND syndromeXp11.2348,521,807missense*EBP*Hypomorphic variant**300960Nonmosaic; ID; short, scoliosis; abnormal digits; cataracts and dermatitisHeterozygotes are usually unaffectedNDCongenital disorder of glycosylation CDG2MXp11.2348,903,182*SLC35A2*UDP galactose transporterLoss of function300896All affected males are mosaicsFemales are affected with infantile epileptic encephalopathyAffected females with truncating variants are highly skewed toward wild type; one female with de novo splice site variant had random XIWBC*AR***Chronic granulomatous diseaseXp21.1-11.437,780, 016*CYBB*Cytochrome B Beta subunit**306400Severe bacterial infectionsDiscoid lupusRare, severely affected female due to skewingNoWBC, buccal*AR***CGD (large study of 93 females only)Xp21.1-11.437,780, 016*CYBB***306400Not applicableMilder symptoms associated with higher dehydrorhodamine oxidation (DHR); low DHR associated with manifestationsNo progressive skewing over timeSevere carriers had low DHRSisters & twins highly correlated, but not with mothersWBC%DHR+**Immunodeficiency 34Xp21.1-11.437,780, 016*CYBB*missense & nonsense variant**300645Severe mycobacterial infections (some TB)Rare femaleND**Coffin--LowryAllelic to XLMR 19Xp22.1220,149,910*RPS6KA3*(RSK2)Small deletions & small duplicationMissense variants**303600ID; short stature; abnormal facies, gait, & fingers; microcephalyMilder ID than maleYes, all seem to have significant skewing; direction not clear save for 2 mothers with predominant wild type cellsWBC*AR RSK2***X-linked mental retardation 19Xp22.1220,149,910*RPS6KA3*(RSK2)Hypomorphic**300854Moderate ID with no other anomaliesMilder nonsyndromic IDNDCoagulation factor 8Xq28154,835,787F8306700Severe \<1%, moderate 2--6% or mild 6--30% residual activityMost heterozygotes have 50% so are clinically normal; affected if homozygous mutants or if XI skewedNo, but skewing causes manifestations.Familial skewing in manifesting heterozygotesWBC*AR*Coagulation factor 9Xq27.1139,530,719F9300746Affected are mainly malesAffected females usually have skewed X-inactivation or are homozygousNo, but severe skewing responsible for manifesting heterozygotesWBC*AR***Cornelia de Lange syndrome5% cases attributed to** ***SMC1A*(Cornelia de Lange, 2)Xp11.2253,374,148*SMC1A*Missense**300590More severe and fetal lethalID, facial dysmorphisms, seizures, limb abnormalitiesMost of the affected are femalesID, poor growth, microcephaly, dysgenesis of corpus callosumEscape geneND**Cornelia de Lange, 2Xp11.2253,374,148*SMC1A*Truncating variants**300040Fetal lethalInfantile epilepsyND**Cornelia** **de Lange5Allelic with XLMR Wilson--TurnerXq13.272,329,515*HDAC8***300882Facial dysmorphism;ID; multiple congenital abnormalitiesMilderExtreme, with mutant allele inactiveWBC*AR***XLMR Wilson--TurnerAllelic with Cornelia de Lange 5Xq13.272,329,515*HDAC8*Point variants**300269ID, microcephalyCraniofacial deformitiesMilderYes, extremeWBCCraniofrontonasal syndromeXq13.168,828,996*EFNB1*Heterozygous loss of function304110HypertelorismCraniosynostosis; craniofacial asymmetry; hypertelorism; frontonasal dysplasia; skeletal abnormalitiesNo, variant produces cellular interferenceBlood,cranioperiosteum*AR* immunochemistryCreatine transporter defectXq28153,687,925*SLC6A8*300352ID, speech delay, seizuresMilderNoSkin fibroblasts, blood, hair roots*AR*Danon diseaseXq24120,426,147*LAMP2*300257ID, cardiomyopathy,skeletal muscle weaknessLater onsetDiscordant identical twins; complete skew for affectedSkew responsible for heterozygous phenotypeIPS T cells*AR***Deafness X-linked 1Allelic with Charcot--Marie--Tooth 5Xq22.3107,628,423*PRPS1***304500Phenotypic spectrum with Charcot--Marie--Tooth Males more severe than femalesFemales have mild high pitch hearing lossNDDeafness, X-linked 4Xp22.1221,705,971*SMPX*300066Nonsyndromic postlingual hearing lossEarlier onset in males 2--10 years (mean 3.3 years)Onset 3--48 years (mean 28.8)XI skewing influences phenotypeWBC*AR***Dent disease1Xp11.2349,922,595*CLCN5***300009NephrolithiasisProteinuriaHypophosphotemic ricketsLess severe;rare hypercalciuria;almost never chronic renal diseaseFirst cases show 1/1 and 2/4 cases of extreme skewing toward mutant in affected femalesWBC & urine sediment*AR* and deep sequencing**Dent disease 2Xq26.1129,540,258*OCRL1*Mild variant of Lowe syndrome**300535Proteinuria; Hypercalcemia; Nephrocalcinosis. No renal tubular acidosis,Heterozygotes not affectedND**Dent disease 2 DigenicXp11.23**,**49,922,595Xq26.1129,540,258*CLCN5*, OCRL1(digenic)**300009300535Abnormal facies, ocular abnormalities, rickets,delayed growthHeterozygotes not affectedYes, severeWBCmRNADiabetes insipidus (nephrogenic)Xq28159,902,624*AVPR2*30480090% are X-linked (10% are autosomal); inability to concentrate urine;unresponsive to antidiuretic hormoneHeterozygotes not affectedAsymptomatic heterozygotes have random XI(4 heterozygotes normal with 50--60% XI) Skewing toward mutant leads to diseaseWBC*AR*Dyskeratosis congenitaXq28154,762,741*DKC1*305000Defective telomeres; premature aging;bone marrow failureNone or milderYes, extremeWBC, buccal multiple tissues*AR***Dystonia parkinsonism (XDP)Filipino typeXq13.171,366,219*TAF1*Retrotransposon insert**314250Adult onset dystonia and symptoms of Parkinson diseaseMost heterozygotes not affected; a few affected have mild dystonia, later onsetmanifestors said to have XI skewedtoward mutant, but no studies documentedND**XLID 33Xq13.171,366,219*TAF1*Missense variants**30096612 boys (9 families); global delay; syndromic ID hypotonia; facial dysmorphism; microcephalysacral caudal remnantHeterozygotes not affectedYes, 100% skewing toward normal alleleWBC*AR* &*RP2* (only WT allele in RNA confirmed by PCR)**Ectodermal dysplasia and immune deficiencyXq28154,542,211*IKBKG*Hypomorphic variants with NF Kappa B activation**300291Fetal lethal or Dysglobulinemia. Recurrent infections, OsteopetrosisAbnormal teethHeterozygotes not affectedYes, severe, with gradual elimination of mutant T cellsT cells*AR*Ectodermal dysplasiaXq13.161,616,085*EDA*Akin to tabby mousemissense, nonsense deletion, & splice junction variants305100Defective skin, hair, nails & teethVariant interferes with rounding of cells by the cell membraneVariable severitySkewing correlated with disease severityNoWBC*AR*Epileptic encephalopathy early infantile, 1Xp21.325,003,693*ARX*308350Spasms without brain malformationsMilder than malesND**Epileptic encephalopathy early infantile, 2Xp22.1318,425,604CDKL5deletions**300672Infantile seizures, global delay subtle dysmorphic features; most die earlyMilder than malesHowever, most heterozygotes affected...Males may die in utero? (32 deletions in females vs. 3 in males \[Decipher\])No skewingWBC*AR***Epileptic encephalopathy early infantile, 2Xp22.1318,425,604*CDKL5*missense**300672Some overlap with Rett; profound retardation and EEG abnormalitiesFemales less severe More apt to have hand stereotypies than malesEpileptic encephalopathy, early infantile, 8Xq11.163,634,966Collybistin*ARHGEF9*300429Heterozygotes not affected unless skewed X-inactivation Manifesting females all have chromosome Translocation or deletion; 2 females with autism and intragenic deletions and no skewingNo, but manifesting requires complete skewing (mutant gene active)Speculation: skewing in brain but not in bloodWBC*AR*Epileptic encephalopathy, early infantile, 9Xq22100,291,643*PCDH19*300088Not affectedMosaic males are affectedID, Infantile seizuresAutismNDHowever, cellular interference thought to play a roleEpileptic encephalopathy, early infantile, 22Xq11.2348,903,182*SLC35A2*300896See *CDG2M*Fabry diseaseXq22.1101,397,790*GLA*301500Progressive heart & kidney diseaseAttenuatedFemales express because not a high uptake enzymeNoSkin fibroblast clones*GLA*Fanconi anemiaXp22.3114,690,862*FANCB*300514Bone marrow failure, predisposed to cancerNo affected femalesYes, extremeWBC*AR***Focal dermal hypoplasiaXp11.2348,508,991*PORCN*Loss of function**305600Fetal lethalMosaic males survive, and have abnormalities, like females (10% of affected)ID; skin atrophy & pigmentation; multiple papillomas; abnormal digits,striated bones; lobster clawMicrodeletions associated with severe skewingPoint variants not skewedWBC*AR***Focal dermal hypoplasiaXp11,2348,508,991*PORCN*** **(missense)**3056002 nonmosaic survivors;Missense variant inherited from motherRandom XI, but asymptomaticNoWBC*AR*Fragile X syndromeXq27.3147,911,918*FMR1*300624XLID; congenital anomaliesVariable, milderYes, slight (full mutation)WBC, skin fibroblasts*FMR1* methylation**Glycogen storage disease 1Xa1 GSD9A1Xp22.1318,892,297*PHKA2*Complete loss of function**306000No PHK activity in liver & RBCsYet mildest form of glycogen storage diseaseNot usually affectedNoSkin fibroblasts*PHK* activity**Glycogen storage disease 1Xa2 GSD9A1Xp22.1318,892,297*PHKA2*Missense enabling partial function**306000No PHK activity in liver;even milder than aboveHeterozygotes not affectedNDHemolytic anemiaXq28154,531,389*G6PD*305900Chronic anemiaHigh dosages of primaquine; Rx for malaria cause hemolysis, if enough cells are mutantYes, slight with ageRBC, WBC*G6PD*Hunter syndrome (MPS2)Xq28149,505,353*IDS*309900MucopolysaccharidosisRarely affected unless skewedNoSkin fibroblast clones*IDS***Hydrocephalus, X-linked (due to aquaductal stenosis) allelic with MASAXq28153,861,513*L1CAM***307000Only males affectedID, spastic paraplegiaSome have clasped thumbHeterozygotes not affectedND**MASA syndromeSPG1Xq28153,861,513*L1CAM*same variants**303350Spastic paraplegia, aphasia,ID, abducted thumb, but no congenital hydrocephalusFamily can segregate MASA or hydrocephalus phenotypesMild ID, abducted thumbsNDHypophosphatemic ricketsXp22.122,032,324*PHEX*307800Short stature; rickets;bone deformitiesHeterozygotes variably affectedNDIchthyosisXp22.317,147,289*STS*308100Extensive body ichthyosis,corneal opacitiesLate corneal opacitiesExpressed from XINo (point variant)Skin fibroblast clonesEscape gene; 1/3 activity of XA*STS* & *G6PD***Immunodeficiency 33Xq28154,542,239*NEMO*** **variants disrupt leucine zipper**300636Infections limited to mycobacteriaHeterozygotes not affectedND**Incontinentia pigmenti IP2Allelic with immunodeficiency 33Xq28154,542,239*NEMO**IKBKG*** **variantsUsually deletions eliminating NF Kappa B activation**308300Fetal lethal usually; milder (hypomorphic) *IKBKG* variants lead to osteopetrosis in males onlyCell death causes rash along Blaschko linesAbnormal hair and teethFemales with hypomorphic IKBKG variants do not have osteopetrosisYes, severe skewing toward wild type, even with milder variants that permit male survivalBlood, WBC, Skin fibroblast clones*HPRT* & G6PDImmunodysregulation, polyendocrinopathy, and enteropathy (IPEX)Xp11.2349,250,435*FOXP3*(*Scurfin*)*Scurfy* in mice304790Immunological disorder; diabetes mellitus, dermatitis and enteropathy, onset in infancy; death by 2 years unless treated by immunosuppression and blood cell transplantation;absence of islets of Langerhans; presents as severe diarrheaHeterozygotes not affectedND**Kabuki syndrome 2Xp11.344,873,174*KDM6A*** **or** ***UTX*(mediates removal of trimethylation of histone H3, at HOX promoters**,**demethylates H3K27; methylates H3K4)**300867IDDwarfism, Kabuki facies, skeletal abnormalities; UTY protectsLike malesSome say females less severe than males---perhaps due to skewing disfavoring deletionsEscape may not protect females more than males as males also have an allele (UTY) on their Y chromosomeIf deletion, then skewed; if variant, not skewedEscapes XIWBC*AR***Keipert syndromeAllelic with Simpson--Golabi--Behmel syndromeXq26.2133,300,102*GPC4*Missense variantsDuplications cause Simpson--Golabi--Behmel syndrome**301026Craniofacial dysmorphisms; foot and hand abnormalities;mild intellectual disabilityCarrier females are clinically unaffected, because all are \>90% skewed toward wild typeYes, severe in bloodWBC*AR***Kelly--Seegmiller syndrome(gout, X-linked)Allelic with Lesch--Nyhan syndromeXq26.2134,460,164*HPRT*308000(partial, \<95% deficiency)**300323Uric acid stones leading to gouty arthritisHeterozygotes not affectedNoWBC**Lesch--Nyhan syndromeAllelic with X-linked goutXq26.2134,460,164*HPRT*308000(\>98% deficiency)**300322ID,spastic cerebral palsy,uric acid stones, self-destructive bitingHeterozygotes not affectedYes, severe (blood)No in skin because of gap junctionsRBC, WBC, skin fibroblastclones*HPRT, G6PD*Lissencephaly & agenesis of the corpus callosumXq22.3-q23111,293,778*DCX*300067ID, brain malformation due to neural migration defect seizuresMild epilepsy (subcortical band heterotopia) or normalNoBlood*AR*Lowe syndromeXq26.1129,540,258*OCRL1*309000ID; cataracts; rickets; aminoaciduriaHeterozygotes not affected(100%) in one manifesting heterozygote unrelated to variantWBC*AR*Severe systemic lupuserythematosisXp22.212,867,071*TLR7*300365Rarely affected, except if XXYFemales 9 times frequency of malesNDEscape from inactivation in all females;B lymphocytes, monocytes and plasmacytoid dendritic cellsLymphoproliferative syndrome 2 XLP2Xq25123,859,811*XIAP* inhibitor of apoptosis*BIRC4*300079Pancytopenia, splenomegaly,pancolitisUsually heterozygotes not affectedOccasionally female affected due to skewing toward mutant cellsYes, in hematopoietic cellsWBC*AR*Lymphoproliferative syndrome*XLP1* (Duncan disease)Xq25124,346,281*SH2D1A*308240300490Severe immunodeficiency especially after EB virus infection; severe or fatal mononucleosis; acquired hypogammaglobulinemia;hemophagocytic lymphohistiocytosis (HLH), and/or malignant lymphomaNo reported affected females (probably because both skewing plus exposure to EB virus needed)Carrier female had complete skewing toward wild type in NK cells but not in T or B cellsWBC*AR***Mediator complex subunit 12MED12Allelic with Lujan--Fryns syndrome (309520); Ohdo syndrome (300895); Opitz--Kaveggia syndrome (305450)Xq13.171,118,595*MED12*** **or** ***HOPA*Transcriptional activator & repressorDifferent variants cause different syndromesMissense variant**300188ID plustall stature(all hemizygous missense variants; different missense variants in same gene)ID plus macrocephaly; hypotonia; absence of corpus callosumInfrequent & milderSee below**Lujan--Fryns SyndromeXq13.171,118,595*MED12*** **or** ***HOPA*** **point variant in exon 22**309520Marfanoid habitus; long, narrow face; moderate ID;Heterozygotes not affectedND**Ohdo syndromeXq13.171,118,595*MED12*** **or** ***HOPA*Missense variants**300895Blepharophimosis; ptosis;cryptorchidism; IDHeterozygotes not affectedND**Opitz--Kaveggia syndromeXq13.171,118,595*MED12*** **or** ***HOPA*Missense variantsC-T transition in exon 21**305450ID; macrocephaly; hypotonia & imperforate anus; partial or complete absence of the corpus callosum; often cryptorchidismMuch milder; hypertelorism; normal IQVariable; Four of 18 heterozygotes showed significant skewing but in different directionsWBC*AR* & *FMR1***Melnick--Needles syndromeSee OPD1Xq28154,348,530*FLNA***3093501 of 4 otopalatodigital syndromes caused by variants in *FLNA*; most are severe; prenatal mortality or perinatal deathSevere congenital abnormalitiesMost affected have much milder phenotype;mild deformity of bonesYes, likelyskewed toward the normal allele because of cell selectionWBC*AR***Menkes syndromeAllelic with occipital horn syndrome & spinal muscular atrophyXq21.177,910,655*ATP7A*Truncation**309400Copper deficiencyHeterozygotes not affectedYes, severeCaveat: 15-kb deletionWBC, lymphoblasts,skin fibroblasts*AR*Methylmalonic acidemiaAlso referred to as XLMR 45Xq28153,947,555*HCFC1*Host cell factor C1300019Missense309541Nonsyndromic IDNormal IQHighly skewed XIYes, severeWBCData not shown**Microophthalmia syndrome 2 (MCOPS2)Allelic with OFCDXp11,440,051,245*BCOR*** **300485** **(See OFCD)Premature stop codons**300166Male lethalCongenital cataract, microopthalmiaCardiac abnormalitiesDental abnormalitiesNDMicrophthalmia, syndromic 7 (MCOPS7)Xp2211,111,331*HCCS*microdeletions300056Male lethalDue to OXPHOS defectWide spectrum ranging from asymptomatic to corneal opacity;microphthalmia;linear skin defects; microcephaly; cardiac defectsSevere; complete or moderate (\>80%) skewing Favoring normal allele (in blood cells)WBC*AR, MAOA, PGK FMR1*Monoamine oxidase A deficiency (Brunner syndrome)Xp11.343,654,906*MAOA*300615Mild ID; aggressive impulsive behaviorHeterozygotes not affectedNDMuscular dystrophy,DuchenneXp2131,119,218*DMD*310200Muscular dystrophyMild IDOnly when unrelated skew favors mutant cellsNoWBC*AR*Muscular dystrophy,Emery--DreifussXq28154,379,235*EMD*310300Muscular dystrophy;heart arrhythmiasNo affected femalesNDMyotubular myopathyXQ28150,673,142*MTM1*300415Respiratory failure during 1st year; severe hypotoniaAsymptomatic, or mild weaknessSome females skewed and symptomaticOne female skewed 70:30 in muscle, and 55:45 in bloodNO or NDHistology (I think) looking for ragged fibers55:45 method not presented**Neurodegeneration with brainiron accumulation (NBIA5)Xp11.2349,074,432*WDR45*** **(all de novo)Most truncating or partial deletion300894**Fetal lethal,Mosaics survive to be affectedStatic encephalopathy of childhood with neurodegeneration in adulthood;parkinsonism; dystonia; dementiaOnly rare, severely skewed toward wild type females survive to manifestWBC*AR***Xp11.2349,074,432*WDR45**BPAN*** **variant300894**Occasional missense variant or germline mosaicism, but most males die in uteroInfantile spasms; developmental delay; ID; absent to limited language; Parkinson disease and dystonia develop with ageSkewed X-inactivation 2:98 in 11-year-old femaleSeveral older females with normal allele preferentially inactivatedWBC*AR?*Neurite extension & migration FactorXq13.374,732,855*NEXMIF* formerly *KIA2022*See *XLID98*300524XLIDLess severeNo36--64%WBCMethylation?Night blindness (congenital)type 1A *CSNB1A*Xp11.441,447,459*NYX* (nyctalopia)310500Myopia and night blindness; rod function absent14 daughters of 9 affected males were not affectedHowever, some heterozygotes are and may reflect skewing---or are homozygous for the variantNDNight blindness (congenital stationary incomplete) type 2AXp11.2349,205,062*CACNA1F*300071Nonprogressive retinal disorder with myopia and nystagmusNo deterioration6 obligate carriers had no symptomsNDNystagmus 1 (congenital)Xq26,2132,074,925*FRMD7*310700Infantile, periodic, alternating53% of carriers are affectedSome have skewed X-inactivationFindings not interpretablePerhaps wrong tissue analyzedActual data not shownOne normal skewed; other normals at 50--60%Four affected skewed; two nonskewed*AR*Ogden syndromeSome variants cause microphthalmia syndrome (309800)Xq28153,929,224*NAA10*300855Delayed psychomotor development; dysmorphic facial features; scoliosis, and cardiac dysfunction with long QT syndrome1 severe female (with loss of function variant; another mild IDWide spectrum depending on nature of variant; females with same variant as males are usually milder4/4 nonaffected Heterozygotes have 90-100% skewingWBC*AR***Oculofaciocardiodental syndromeMicrophthalmia syndrome 2Xp11.440,051,245*BCOR*** **null**300166Death in uteroOFCDEarly onset cataractsRadiculomegaly of canine teethCardiac septal defectsFacial dysmorphismSome skewing toward wild type**X-linked BCOR-related syndromeLenz microphthalmiaXp11.440,051,245*BCOR*** **variantC to T transition**300485Microphthalmia syndromeSevere microphthalmiaSome variants have no eye abnormalities, but MRHeterozygotes not affected100% skewing**Orofaciodigital syndrome (OFD1)Allelic with Simson--Galabia--Beheld syndrome 2 & Joubert syndromeXp22.213,734,712*OFD1*** **(*CXORF5*)311200**Fetal lethalA ciliopathyMalformations of face & digits; polycystic kidneysNo human gene escapes XIIn mice no escape and neonatal mouse females die of polycystic kidneysWBC*AR***4**-**bp deletion in** ***OFD1*** **causing frameshift**Mother (not affected) has random XI but affected daughter is skewed toward mutant allele**Joubert syndrome 10Allelic with Simpson--Golabi--Behmel, and OFD1XP22.213,734,712*OFD1*Small deletions**300804Ciliary dysfunctionHypotoniaCerebellar ataxiaHeterozygotes not affectedND**Simpson--Golabi--Behmel syndrome type 2Allelic with OFD1Xp22.113,734,712*OFD1*4**-**bp deletion**300209One family of 9 males; most die early but one had severe ID, facial dysmorphisms, obesity, & repeated respiratory infections; respiratory cilia disorganized and uncoordinatedHeterozygotes not affectedND**Oropalatodigital syndrome 1Xq28154,348,530*FLNA*Mildest of spectrum**311300Cleft palate, conductive hearing loss; mild skeletal abnormalities & renal failureSome mild symptomsNo, but skewingcauses manifestationWBC*AR***Oropalatodigital syndrome 2Xq28154,348,530*FLNA*Gain of function variants**304120Disabling skeletal anomalies, variable brain, cardiac, intestinal anomaliesMilder symptoms, some facial dysmorphism**Melnick--Needles syndromeXq28154,348,530*FLNA*Most severe**309350Fetal lethalSkeletal dysplasiaYes? Skewing in blood toward normal in 3 affected heterozygotes, but FLNA interacts with AR so assay may not be validWBC**Frontometaphyseal dysplasiaXq28154,348,530*FLNA***305620Frontal bone overgrowth, scoliosis, facial dysmorphism; increased bone density; occasional renal abnormalityNormal, or mild hyperosteosisNDOrnithine transcarbamylase deficiencyXp11.438,352,527*OTC*311250Urea cycle disorder;males die in infancy of severe disease unless treated85% are symptomatic with hyperammonemia20--30% activity not enoughNo, but skewing in liver, not WBCs, corresponds with severityWBC & LiverPDC deficiencyXp22.1219,343,892*PDHA1*pyruvate dehydrogenase complex, E1-ɑ polypeptide 1312170a) Neonatal lactic acidosis; encephalopathy; brain malformations; early deathb) Infantile or childhood-onset Leigh syndromec) Milder relapsing disorder of ataxia dystonia and peripheral neuropathyDysmorphic features; microcephaly; moderate or severe psychomotor delay; spastic di/quadriplegia & epilepsy (cortical atrophy, cyst & corpus callosum agenesis);all heterozygous; more severe variant than in malesMissense variants are milderNo, but skewing determines severity of phenotypeWBC*AR*Pelizaeus--MerzbacherXq22.2103,776,505*PLP1* point variantOften duplications of Xq22.2312080Myelin leukodystrophySpastic diplegiaNo symptoms or milder;Rare female affected due to skewing toward mutant cellsSome mild affected have no skewing because variant not severe enough to skewDuring CNS development, oligodendrocytes with severe *PLP1* mutant alleles are negatively selected (apoptosis) in favor of wild type cells, with cell type specific skewed XIWBC, lymphoblasts*AR*PIH1D3Xq22.3107,206,610*PIH1D3* formerly *Cxorf41*Expressed primarily in testes300933Primary ciliary dyskinesia;nonsyndromic ODA; respiratory infections; chronic otitis; infertility with mutant spermHeterozygotes not affectedNormal fertilityND**Phosphoribosyl pyrophosphatesynthetase 1 spectrumXq22.3107,628,423*PRPS1*Gain of function**300661Hyperuricemia; gout; deafness and neurological misfunctionHis mother had gout, uric acid stones and hearing lossND**Charcot--Marie--ToothXq22.3107,628,423*PRPS1*Reduced expression**311070Peripheral neuropathy; deafness; visual impairment;no increased uric acidNot affected or milderVariable skewing consistent with phenotypeWBC*AR***Arts syndromeXq22.3107,628,423*PRPS1*Reduced expression**301835ID; hypotonia; ataxia; hearing impairment and optic atrophyMilder but continuous spectrum depending on extent of skewingVariable skewing consistent with phenotypeWBC*AR***DFNX1Xq22.3107,628,423*PRPS1*Missense variant40--70% reduced activity**304500DeafnessSpectrum of phenotypesUsually milderNDProtoporphyria (X-linked erythropoietic)Xp11.2155,009,054*ALAS2*Increased activitygain of function300752RBC porphyria11 females vary in phenotype with skewing of XI correlated with degree of severityExample of no X-linked dominant diseaseNo selection, but skewing influences phenotypeBlood DNA*AR* & *ZMYM3*Raynaud--Claes syndromeXp22.210,156,944*CLCN4*Chloride/hydrogen ion exchangertruncated and missenseframeshift300114Severe ID & epilepsyImpaired languageMilderNot shown;No obvious selectionWBC?? Poor studyRenpenning syndromeXp11.2348,897,861*PQBP1*Polyglut binding protein 1300463MR; short stature, microcephalyUnaffected, but skewed XIHighly skewedWBC*AR, FMR1***Retinitis pigmentosis 3Xp11.438,269,162Loss of function; hot spot in exon 15*RPGR***300029Inherited choroidal retinal degeneration; destroys rod photoreceptors; become blindAll heterozygotes have tapetal-like retinal reflex; some heterozygotes are affected---usually milder, but variable; rarely legally blindND**X-linked cone--rod dystrophyXp11.438,269,162variants in alternate exon 15*RPGR***304020Progressive loss of visionNot affected, but detectable by visual testingND**Syndromic retinitis pigmentosaXp11.438,269,162*RPGR***300455RP3 with sinorespiratory infections, with or without deafnessOften affected, but milderND**Rett syndromeXq28154,021,572*MECP2*point variant**312750300005Fetal lethal;mosaic males have Rett syndrome; some males without obvious mosaicism survive;severity dependent on mosaicism & variantMR; arrested development; impaired speech; handwringingNo, unless large deletion;Blood DNA does not always reflect brain DNAWBC*AR***Lubs XLIDAllelic with Rett syndromeXq28154,021,572*MECP2*** **duplication**300260Affected males have Rett phenotype; moderate to severe ID; seizuresUnaffected because of extreme skewingExtreme skewingWBC*AR***Sick sinus syndromeXq28154,021,572*MECP2*** **deletion(0.6 deletion effecting TDR)**Not yet givenAutonomic NS affected in two brothersMilder symptomsExtreme skewing in unaffected motherWBC*AR*Simpson--Golabi--Behmel syndrome type 1Xq26.2133,535,744*GPC3*Duplication of *GPC3* & *GPC4* produce some affected females, but skewing toward mutant needed312870Congenital malformations & overgrowthID, macrocephaly, cleft palateRare; usually unaffected or much milderRarely affected;Female with a small Xq26 microduplication is affected; she has random XINo; skewing toward mutant produces symptomsNormal females not skewed?**SCIDX1Severe combined immunodeficiencyXq13.171,107,403*IL2RG***300400B- & T-cell immunodeficiencyHeterozygotes not affectedYes, extremeT & B cellsCell count**CIDX1Xq13.171,107,403*IL2RG***312863Milder allele of SCIDSHeterozygotes not affectedYesPredominantly affects T cells,*AR*Tonne--Kalscheurer syndromeXq13.274,582,975*RLIMRFN12*300379Global developmental delay; ID; subtle facial dysmorphism; multiple congenital anomaliesautism; severe feeding problemsHeterozygotes not affected unless severeloss of functionAll 4 females with mild skeletal anomalies were extremely skewed (not shown), and normal females also skewed Direction of skewing not shownWBC*AR***ThrombocytopeniaAllelic with Wiskott--AldrichXp11.2348,683,752*WAS*hypomorphic alleles**313900Decreased number of platelets; bleeding tendencyRare, presumably due to chance skewingReported as random but results not interpretableWBC*AR***Wiskott--Aldrich syndromeXp11.2348,683,752*WAS*severe loss of function**301000Deficiency of B & T cells, leukocytes & thrombocytesNo affected femalesYes, severeT, B cells & granulocytes*AR***XLID 1 & 18, 78Allelic with1Q motif and SEC7 Domain18M,19F XLIDXp11.253,225,783*IQSEC2*Nonsense & duplications**300522ID nonsyndromicSome have learning disabilitiesND, escapes XI**IQ Motif and SEC7 Domain18M,19FXLIDallelic with XLIDR 1, 18 and 78Xp11.2253,225,783*IQSEC2*(Shapes dendrite morphology) Truncating variants**300522ID nonsyndromic; 95% have epilepsyvariants reduce axon length in mice; de novo or maternalMilder ID 70% epilepsy without seizures---all de novo 4/5 affected had random XI1 skewed 2 nonaffected carriers had random inactivationNo, 1 severely affected female favoring mutant alleleHuman gene escapes XI, but not mouse geneBlood DNA*AR*XLID 12Also called THOC2 XLIDXq25123,600,562*THOC2*300395Mild--moderate IDSpeech delayNeurological developmental defectHeterozygotes not affectedXLID 15Cullin RingCabezas typeXq24120,524,588*CUL4B*300354ID (IQ 29--54), short stature macrocephaly, hypogonadism (small testes), tremor, abnormal gaitRarely mild tremor, ticsMice die due to PXIObligate heterozygotes have large handssome learning disabilityYes, severeWBC**XLID TurnerXp11.2253,532,095*HUEW1*E3 ubiquitin ligase**300697**Microduplications**309590Moderate to profound ID, global delay with macrocephalynonsyndromicHeterozygotes not affectedYes & no: severe favoring wild type in some females with microduplicationsWBC*AR***Xp11.2253,532,095*HUEW1*Missense variantscodes E3 ubiquitin ligase**309590Moderate to profoundXLID; short stature; speech pathology; small hands & feetHeterozygotes not affected**Xp11.2253,532,095*HUEW1*De novo loss of function**309590No affected males seenFemales with dysmorphic XLID; craniostenosis; Chiari malformationSevere skewing favoring mutant in affected femalesXLID Claes--JensenXp11.2253,176,276*KDM5C/JARIDC*314690Also, *SMCX*300534Short stature; microcephaly;abnormal facies;developmental disabilityMilderYes, severe favoring wild type in 4 unaffected heterozygotesWBC*AR*XLID Houge type(MRXSHG)Xp22.2*CNKSR2*Deletions; frameshifts; truncating variants301008Delayed psychomotor development; poor verbal skills; microcephaly; focal seizuresMild learning disability or nonaffectedSpeculation that skewed XI prevents severe effects in brain, but not shown, nor is it neededNot shown, but 2 manifesting heterozygotes had 56:43 and 20:80 XI ratios*CNKSR2* is only expressed in brain tissueWBCXLID SideriusXp11.2253,936,679*PHF8*Microdeletion (470 kb)300263ID; abnormal facies; cleft palate/lipHeterozygotes not affectedYes, severe favoring wild type in unaffected mother,WBC*AR*XLID 90Xq13.170,444,834*DLG3*Truncating300850Moderate to severe nonsyndromic IDHeterozygotes are usually not affectedMajority of heterozygotes have random XI Skewinginfluences phenotype**XLID 98Xq13.374,732,855*NEXMIF*** **(KIAA2022)Hypomorphic loss of function**300524Severe ID; poor speech postnatal growth retardationStrabismusUsually not affected unless truncating variants (see below)Normals not studied (one inversion showed skewing)1 affected female not skewed (73:27)WBC*AR***Xq13.374,732,855*NEXMIF*(KIAA2022)Heterozygous truncating variants---all loss of function**300524NA14 females withintractable epilepsy,milder ID6/7 had random XI1/7 (the most severe) had completely skewed XI favoring mutant cellsWBC? Data not shown**XLID 99 Male restricted(MRXS99F)Xp11.441,085,419*USP9X*Nontruncating missense variants, no effect on catalytic activity**300919ID, hypotonia, aggression,thin corpus callosum; loss of hippocampal-dependent learning & memoryFemale carriers identified and none affectedND*USP9X* escapes XI in some tissues, not in others**XLID 99 Female restrictedXp11.441,085,419*USP9X*30072Point variants leading to truncationDe novo loss of function variants**300968Male lethalTruncating variants are lethal in malesMR; short; choanal atresia; heart defects; polydactyly;hearing loss;skin pigmentation (Blaschko)Affected females may be skewed \>90% but test does not show direction; *USP9X* escapes XI in some tissuesWBC*AR***XLID 102XXp11.441,333,307*DDX3X*** **complete loss of function 300160**300958LOF lethal (Decipher shows loss of males)LOF causes MR, spasticity, ASDHeterozygotes with hypomorphic variant are not affectedNo*DDX3X* escapes XIHomolog on Y**Xp11.441,333,307*DDX3X*Hypomorphic variants**Occasional males have nonsyndromic IDNo diseaseND**XLID 106Xq13.171,533,103*OGT*Missense**300997IQ 49--61; facial dysmorphismsMild spastic diplegia plus other congenital abnormalitiesEmbryonic lethal (mice)Females normal but highly skewed X-inactivationNo reference providedIn mice, if maternal allele mutant then embryonic lethal**XLID 106Xq13.171,533,103*OGT*Missense**300997Usually only malesTwin sistersXLID plus some facial dimorphismsEach had 93:07 Direction of skewing not knownWBC*AR*XLID 107Xq24119,538,148*Cxorf56*301012Frameshift variant3010135 males: Moderate ID, Long narrow faceMilder1 female with no skewing (57%) but nonaffected carriers were skewedNormalSignificantly skewed (76--93%)WBC*AR***XLID Wilson--TurnerSee Cornelia de Lange 5Xq13.272,329,515*HDAC8*Point variants**300269ID, microcephalycraniofacial deformitiesMilderYes, extremeWBC*AR*The X-linked diseases in this table are disorders with available information about heterozygous females. They are listed with their disease name, their X map locus (the location of the gene on the X chromosome, including its 5' start site, from OMIM). These data are followed by the symbol for the variant gene, the protein that is deficient and the nature of the variant if known. In each case, although the phenotype is variable, the most common one is described. Cell selection favors cells expressing the normal allele, unless otherwise indicated. In all cases chance skewing, that is skewing unrelated to the variant, influences the phenotype. Allelic disorders are indicated in bold.*AR* androgen receptor, *ASD* autism spectrum disorder, *ID* intellectual deficiency, *LOF* loss of function, *SCIDS* severe combined immunodeficiency syndrome, *XLID* X-linked intellectual deficiency, *WBC* white blood cells.

SEX DIFFERENCES ARE DUE TO X-INACTIVATION {#Sec2}
=========================================

The sex differences in the effect of X-linked pathologic variants is due to our method of X chromosome dosage compensation, called X-inactivation;^[@CR9]^ humans and most placental mammals compensate for the sex difference in number of X chromosomes (that is, XX females versus XY males) by transcribing only one of the two female X chromosomes. X-inactivation silences all X chromosomes but one; therefore, both males and females have a single active X.^[@CR10],[@CR11]^

For 46 XY males, that X is the only one they have; it always comes from their mother, as fathers contribute their Y chromosome. However, because X chromosomes are silenced in a random fashion, females usually have two kinds of cells in every tissue; those with their maternal X active and those with an active paternal X. Females are protected to a large extent because their two X chromosomes most often differ in genetic content.

Sex differences in diseases due to deleterious variants encoded by the X chromosome originate from the sex difference in the expression of the variant allele; if present in male tissues, it is expressed in every cell, but if present in female tissues, the variant is usually expressed in only half the cells (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Comparing the effect of a single pathologic variant in females and males.Adapted from Fig. 1 of Franco B, Ballabio A. Curr Opin Genet Dev. 2006;16:254--259, with permission of authors. In females: On average, the ratio of the two cell types (expressing normal or variant alleles) is approximately 50:50. However, the ratio may differ because of chance, or a selective disadvantage for cells expressing the variant. Extreme divergence from the 50:50 ratio, known as skewing of XCI, may differ from tissue to tissue, and among individuals influencing the severity of the phenotype. Cell selection usually takes place only in cells which express the variant and which do not receive the essential gene products from the normal cells that make them. In males[:]{.ul} an X-linked variant is expressed in every cell. The exceptions are males with somatic mosaicism: like females, mosaic males will express both variant and normal allele, and the phenotype depends on the admixture of variant and normal cells.

FEMALES ARE MOSAICS {#Sec3}
===================

A woman is less susceptible to the pathogenic variants in genes on her active X chromosome because the variant is not expressed in all her cells.^[@CR12]^

FEMALES CAN AMELIORATE THE EFFECTS OF PATHOGENIC VARIANTS {#Sec4}
=========================================================

Most women do not manifest X-linked disorders because (1) they are not homozygous for the pathogenic variant, and (2) their variant cells (those expressing the deleterious allele) receive sufficient gene product to carry out the essential metabolic function from the cells that transcribe the normal allele.

The crucial protein is provided in one of two ways. Either the cells that can make it transfer it to the deficient cells, or, if this cell-to-cell transport does not take place, the lack of functional protein may cause the deficient cells to divide less efficiently, and so they are eventually overgrown by the cells that make the normal protein. Yet, in various tissues, cells differ in their capacity to transfer gene products and so there may be differences within body tissues in the ability of the normal cell to share, or the abnormal cell to survive^[@CR12]^ (Fig. [1](#Fig1){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}).

FEMALES ALMOST ALWAYS HAVE LESS SEVERE MANIFESTATIONS OF X-LINKED DISEASES {#Sec5}
==========================================================================

For most X-linked deleterious variants, the manifestations are less severe in females than males. The mix of normal and abnormal cells moderates females\' disease. Yet, there are disorders in which the variant is so lethal that most males with severe deficiency of the gene product die in utero. Because the only survivors are females or mosaic males, who also have a mix of variant and normal cells, they are the ones with nonlethal manifestation of the disorder. X-linked diseases, such as incontinentia pigmenti, or orofacial digital syndrome type 1, occur only in females or mosaic males.^[@CR13]^

SOME FEMALES ARE MANIFESTING HETEROZYGOTES {#Sec6}
==========================================

Many factors determine if a heterozygote manifests her mosaic variant. Our knowledge of the effect of second variants of genes in related pathways on the ultimate phenotype is meager, but suggests that we need to be aware of the potential effect of other relevant genes on any variant. Although Table [1](#Tab1){ref-type="table"} includes only one known instance of digenic X variants (Dent disease 2), one expects there will be more. The effect of digenic variants leading to Dent disease are ameliorated in the heterozygote, who carries both variants on the same X chromosome, as these abnormal cells are strongly disfavored (Table [1](#Tab1){ref-type="table"}).^[@CR8]^ In this case, heterozygotes are much less severely affected than hemizygous males because of the strong cell selection against cells expressing the two variants simultaneously.

EFFECT OF SEX AND X-INACTIVATION ON PHENOTYPE IN X-LINKED DISORDERS {#Sec7}
===================================================================

As I learn about why some heterozygotes express their variants, yet others with the same variant do not, I more fully appreciate the nuances of disease processes and the intricacy of the interdependence between the type of cell, its response to abnormal gene products, and the nature of the disease variant. Table [1](#Tab1){ref-type="table"} shows the effect of pathogenic variants of X-linked genes in males and females. For almost all of the disorders listed, females have less severe clinical manifestations. Table [1](#Tab1){ref-type="table"} also documents the variables that determine if an X chromosomal variant is manifested or not, that is, if products are shared or if normal cells have a selective advantage. The severity of the phenotype is most often attributable to the nature of the variant. Does it completely eliminate the gene's function, or does it allow some gene product to be produced? Variants that disable an essential protein completely are more often seen in females, as males whose only gene is nonfunctional are lost in utero, unless other genes can substitute for it. On the other hand, variants with some residual function may affect only males. In both cases, the female phenotype is less severe, as she has some normal cells that carry out the essential function.

EFFECT OF SHARING GENE PRODUCT BETWEEN CELLS {#Sec8}
============================================

Because it is largely unknown, Table [1](#Tab1){ref-type="table"} does not include the quantity of gene product that must be provided to a cell to replace that lost through a variant. In most cases 50% activity is more than enough, and for many genes, even smaller amounts of product will suffice. This readily explains why many X-linked disorders never affect women. For example, less than 5% of the enzyme HPRT can alter the phenotype from severe hyperuricemia, seen in Lesch--Nyhan males, to gout. Lesch--Nyhan heterozygotes rarely express any features of the syndrome, including gout. In most of her tissues the product of the HPRT reaction, inosinic acid, is transferred from her cells that synthesize it, to those that cannot, through gap junctions, present in all cells of the body except blood cells.^[@CR14]^

Cell sharing also occurs in women who are heterozygous for variants causig X-linked lysosomal diseases. Lysosomes contain many enzymes that break down proteins and lipids. Variants in the genes that encode these enzymes cause diseases by the accumulation of undegraded material within the lysosomes of affected individuals. Fortunately, the deficient cells of the heterozygote can take up the enzyme secreted by the normal cells through a process called endocytosis. Therefore, potential manifestations in carriers of variants of lysosomal enzymes encoded by the X chromosome are generally ameliorated by the transfer of these enzymes from the cells that can make them to those that cannot.^[@CR15]^

EFFECT OF CELL SELECTION IN MOSAIC FEMALES {#Sec9}
==========================================

Because they lack gap junctions, the leukocytes from Lesch--Nyhan heterozygotes do not receive the inosinic acid made by their normal counterparts. Fortunately, the lack of inosinic acid slows the rate of cell division; the normal cells (because the variant is on their inactive X) eventually replace the deficient ones. As a consequence, heterozygous mothers and sisters of Lesch--Nyhan males have only normal blood cells, and in other tissues, their mutant cells share the gene products provided by their normal cells.^[@CR16]^ It takes about ten years for all their abnormal red cells to be replaced^[@CR17]^ because in this case, the selective advantage of the normal allele is relatively small.

The rate of loss of deficient cells can be slow or fast depending on the degree to which the variant is disadvantageous. When selection is intense, that is, when it severely disfavors the cells that express the variant, heterozygous females benefit, as they rapidly lose all their mutant cells. Sometimes the loss of variant cells occurs so early that abnormal cells may never enter a tissue. In cases of immunodeficiencies, like Wiskott--Aldrich syndrome, the growth disadvantage is immediate; the mutant B cell precursors never leave the bone marrow (Table [1](#Tab1){ref-type="table"}).^[@CR8]^

Unfortunately, sometimes it is the variant cell that has the selective advantage. For reasons not yet understood, heterozygotes with the variant causing adrenoleukodystrophy slowly lose their population of wild type cells.^[@CR18]^ Therefore, as they age, they usually manifest some symptoms of the disease. Adrenoleukodystrophy is the only known X-linked disease where the variant allele has a selective advantage. X-linked variants that slow the growth of the expressing cells usually protect females from manifesting them. If one examines the cells from these heterozygotes, one sees highly skewed patterns of X-inactivation in the expressing tissues: eventually, the X with the variant will always be silent (that is, always on the inactive X). Females carrying pathologic variants that produce X-linked mental retardation often have X-inactivation patterns that are highly skewed favoring expression of the wild type gene, protecting them from ill effects of their variant.^[@CR19]^ In such women, the cells that express the variant gene are disfavored.

MANIFESTING HETEROZYGOTES {#Sec10}
=========================

With so many mechanisms available to protect females with an X-linked pathologic variant, one wonders why some heterozygotes manifest any symptoms of a disease. As mentioned previously, if the variant is so functionless that it is lethal to fetal or newborn males, then females with a single mutant allele are the only ones that can have the disease. As Table [1](#Tab1){ref-type="table"} indicates, the severity of the variant can determine if females express the variant or not.

Occasionally, females are the ones to manifest a disease because the variant allele interacts with the normal one, undergoing a process called cellular interference. The most well defined example of this is the craniofrontonasal syndrome, caused by a deficiency of Ephrin-B1 (*EFNB1*).^[@CR20]^ Other members of the ephrin family of proteins can substitute for a deficiency of *EFNB1* in males with the deleterious variant, and as a result, they have minimal clinical symptoms. Heterozygotes, however, have a mixture of mutant and wild type cells; for reasons not yet understood, it seems that such mixtures do not permit ephrin substitutes, and consequently, females have a deficiency more severe than that in males, who can substitute one ephrin for another. It is heterozygosity, not the complete loss of function, that produces the severe disorder. It is the patchwork or mosaic loss of *EFNB1* that disturbs tissue boundary formation at the developing coronal suture. Several forms of infantile epilepsy also show similar cellular interference, but fortunately no other examples are known.

Yet, there are females who express an X-linked pathogenic variant, even though most carriers of pathogenic variants in similar genes do not. For example, females with Fabry disease, caused by lack of the lysosomal enzyme ɑ-galactosidase may have some of the clinical symptoms seen in affected males, whereas carriers of a variant in a gene encoding another lysosomal enzyme, iduronic sulfatase, rarely have any clinical symptoms associated with Hunter syndrome.^[@CR21]^ Both enzymes are made in the lysosomes, and can be transported from the lysosomes of one cell to those of another cell. The two lysosomal disorders differ because iduronate sulfatase is taken up by cells better than the low uptake enzyme, ɑ-galactosidase.^[@CR22],[@CR23]^ This difference in the ability of the lysosome to take up a product is responsible for normal Hunter heterozygotes and manifesting Fabry heterozygotes.

OTHER DETERMINANTS OF MANIFESTING HETEROZYGOTES {#Sec11}
===============================================

One wonders why some heterozygotes express disorders that do not affect most of the others with the same variant. Some females manifest their X-linked variant because it is overexpressed; their variant is expressed in more than half their cells because of skewing in the proportions of normal and abnormal cells. Although random inactivation usually means that 34--68% of heterozygous cells are abnormal,^[@CR12]^ a few heterozygotes have more than 90% variant cells. Such females manifest the disorder because their wild type allele is not expressed sufficiently. These manifesting heterozygotes are often reported in medical journals because they are affected with a disease that usually occurs only in males. In some cases, a chance chromosome translocation or deletion is responsible for the skew, as such abnormal X chromosomes often influence the direction of skewing. X/autosome translocation chromosomes are responsible for the rare females afflicted with Duchenne muscular dystrophy.^[@CR24]^ Maternal isodisomy,^[@CR25]^ early onset monozygotic twinning (known to promote skewing^[@CR26],[@CR27]^), and other extreme skewing of X-inactivation^[@CR28]^ have also been responsible for manifesting heterozygotes (Table [2](#Tab2){ref-type="table"}).Table 2Factors influencing expression of X-linked variant in females.VariantX-inactivationOutcome^a^Number of mutant allelesStrength of variantRandomSkewed To variant^b^Skewed To wild type^c^Escape allele^d^MalesFemalesBiallelic (rare)NANANANAAffectedEqually affected as maleNANANANA+AffectedEqually affected or worse than maleMonoallelicMild to moderate**+**AffectedLess severe or no abnormalitiesMild to moderate**+**AffectedEqually affectedMild to moderate**+**AffectedLess or more severeSevere**+**Fetal lethalExpress variantSevere**+**Fetal lethalLess severeSevere**+**Fetal lethalSevere or lethalSevere**+**Fetal lethalLess or more severeX/A translocation**+**AffectedLess severeX/A translocation**+**AffectedMore severe^a^Male phenotype is given; female phenotype is given relative to male.^b^Variant allele is on the active X.^c^Normal allele is on the active X.^d^Allele is also expressed to a small extent from the inactive X.

Although some skewing may be attributable to abnormalities of the *XIST* locus,^[@CR29]^ such variants occur only rarely. If one *XIST* allele loses function, than that allele is always on the active X. Minor loss of function variants of *XIST* may lead to some skew,^[@CR29]^ but few have been reported. Cell selection and random skewing are the most frequent causes of nonrandom X-inactivation. Random skewing frequently occurs because of events surrounding twinning, and confined placental mosaicism.^[@CR30]^ Often skewing is due to the randomness of the inactivation process, which is stochastic and therefore due to chance. Ten percent of females are \>2 standard deviations from the mean of 50%.^[@CR23]^

Stochastic skewing that favors cells that inactivate the normal *WDR45* allele is responsible for neurodegeneration seen in the rare female infants who manifest the X-linked pathologic variant (*NBIA5*), because their brains accumulate iron. If this disorder is caused by a truncating variant, only mosaic males, or females who are highly skewed favoring the normal allele, manifest the disease, as all other males and females with the variant die in utero. Affected females with hypomorphic variants often skew favoring the mutant allele (Table [1](#Tab1){ref-type="table"}).^[@CR8]^

DEGREE OF CELL SELECTION IS DETERMINED BY THE VARIANT {#Sec12}
=====================================================

The X-linked form of Kabuki syndrome is caused either by point variants or deletions in *KDM6A*. Females with point variants often have Kabuki syndrome, whereas those with the larger deletions silence the X carrying the deletion; hence, they have less severe manifestations.^[@CR31]^

Only a rare heterozygote with a variant in the *PLP1* gene has symptoms of the myelin leukodystrophy associated with Pelizaeus--Merzbacher syndrome, and she invariably shows chance skewing favoring the mutant cells.^[@CR32]^ In addition, during the central nervous system (CNS) development of heterozygotes, the oligodendrocytes with severe *PLP1* disease alleles are negatively selected (apoptosis) in favor of wild type cells, resulting in skewed X-inactivation that is cell type specific.^[@CR8]^

ESCAPE GENES INFLUENCE PHENOTYPE {#Sec13}
================================

Another factor that influences the clinical manifestations of X-linked variants in heterozygotes is the partial expression of genes from the inactive X chromosome.^[@CR33]^ In addition to those genes in the pseudoautosomal region that are expressed on both sex chromosomes, more than 100 genes on the human X chromosome are expressed not only from the active X, but also to some extent from the silent X.^[@CR34]^ They are referred to as escape genes. In fact, such genes do not really escape silencing, as they function to some extent, usually producing 10--30% of the level of transcripts made by the homologous allele on the active X. Yet, this little extra expression of a gene does influence phenotype. For example, male fetuses with pathologic variants causing orofacial digital syndrome all die in utero, unless they have a second X chromosome (i.e., Klinefelter syndrome); human females survive birth and die in their forties, usually from renal failure. However, female mice with the same variant outlive males by only several weeks as they die as neonates due to their polycystic kidneys. The important species difference is that humans, but not mice, partially express the *OFD1* gene from their inactive X.^[@CR13]^ This little extra gene activity is responsible for the difference in age of death of females of the two species. A little extra gene product from the inactive X can ameliorate the effects of an X-linked variant (see Table [2](#Tab2){ref-type="table"}).

The extra product may not be available in every tissue, as there are tissue-specific differences in the expression of escape genes. In several females with a *USP9X* variant, pigment changes along the Blaschko lines and body asymmetry were observed, which is probably related to differential escape from X-inactivation between tissues^[@CR35]^ and Table [1](#Tab1){ref-type="table"}.

Yet, a little extra activity from the inactive X is not always helpful. It seems that expression of the Toll-like receptors on the inactive X is partly responsible for the impressive sex differences in some cases of autoimmune diseases like Lupus and Sjogren disease.^[@CR36]^ Toll-like receptors, encoded by the X chromosome, are signaling pattern recognition receptors that are an integral part of innate immunity. The little extra activity may provide females with better protection against infectious agents, but it may make them more susceptible to autoimmunity. Such disorders are nine times as frequent in females than males and are also increased in Klinefelter XXY males, whereas as Turner females, even those taking estrogens, have the same risk as XY males. It is now thought that the excess manifestations of autoimmune disease in women are due to a complex of issues. Studies in mice show that increasing the expression of the X-linked Toll-like receptors in susceptible mice increases the expression of the autoimmune disorder.^[@CR36]^ It has not yet been shown that affected females and Klinefelter males have greater expression of their Toll-like receptors than those women and XXY males who do not have the disorder.

Other relevant X-linked genes with potential to influence autoimmunity and that escape X-inactivation include *CXCR3*,^[@CR37]^ *KDM6A*,^[@CR38]^ and *CXorf21*, which has been shown to be more highly expressed in women and Klinefelter males than in normal men.^[@CR39]^ In addition, the expression of *XIST* from the inactive X in lymphocytes differs significantly from that of other cells as the *XIST* RNA cloud is dispersed, leading to poorer Barr body formation.^[@CR40]^ No doubt, it is the interaction of several factors that is responsible for the high incidence of autoimmunity associated with having two X chromosomes.

DIFFERENT DISORDERS FROM THE SAME GENE {#Sec14}
======================================

What is increasingly apparent is that variants in a single gene can lead to differently named disorders, because of the specific effect of the variant on production of the gene product. Before variants were identified, diseases were classified by their phenotypes and named by the physician who reported the disease, based on its symptoms. Now, we know that many different phenotypic disorders may be due to variations in the same gene; their effect in the heterozygote reflects the severity of the variant, which has influenced the naming of the disorder. Table [1](#Tab1){ref-type="table"} shows some of these allelic disorders (in bold). Yet, in most cases, no matter the severity of the disease in males, the heterozygous female is better off than the hemizygous male.

Examples of allelic disorders are the different variants in the IKBKG gene, which can cause incontinentia pigmenti (IP) if dysfunction is severe, ectodermal dysplasia if dysfunction is moderate, and immunodeficiency 33 if it is mild. When the pathologic variant is severe (like IP), females may be the only ones that manifest the disorder, as males die in utero. On the other hand, when it is moderate, or mild (like immunodeficiency 33), women may completely escape its pathologic effects (Table [1](#Tab1){ref-type="table"}).^[@CR8]^

Another set of allelic disorders is caused by variants in the *PRPS1* gene, responsible for syndromes of deafness (missense variant leading to reduced expression), gout (gain of function variant), and Charcot--Marie--Tooth disease (more severe reduction of expression), depending on the severity of the specific variant. Again, the heterozygous female always has a less severe phenotype than the hemizygous male. When the male is deaf, the female has high range hearing loss; when he has gout, she has no manifestations. However, when he has optic atrophy and neuropathies, she has much milder manifestations, or none at all (Table [1](#Tab1){ref-type="table"}).^[@CR8]^

There is a spectrum of allelic disorders caused by different variants in the filamin A gene; again females are always less affected than males with the same deleterious variants, and are the only ones affected with Melnick--Needles syndrome, because it is lethal in males (Table [1](#Tab1){ref-type="table"}).^[@CR8]^

There are also allelic disorders caused by different variations in the *MECP2* gene. Rett syndrome results when the gene has a deletion or substitution variant that decreases its function; the loss of function causes a disorder that is usually lethal to unborn males, so that generally only females survive to manifest the disease. However, when the same gene is duplicated (Lubs X-linked intellectual disability \[XLID\], Table [1](#Tab1){ref-type="table"}), the increased function permits males to survive and manifest the disorder, whereas the gene duplication provides the normal allele a selective advantage, so that females escape all manifestations, as the duplicated gene is always on the inactive X (Table [1](#Tab1){ref-type="table"}).^[@CR8]^

Another impressive example of the effect of allelic disorders on sex differences in expression of the disease are variants in the *USP9X* gene (Table [1](#Tab1){ref-type="table"}).^[@CR8],[@CR35]^ As point variants leading to truncation are lethal for the male fetus, the manifestations are confined to females. On the other hand, less severe nontruncated variants in the same gene cause hippocampal related mental retardation, hypotonia, and aggression in males, whereas carrier females have no abnormalities.

MANY X-LINKED GENES ARE ASSOCIATED WITH INTELLECTUAL DEFICIENCY {#Sec15}
===============================================================

The proportion of X-linked variants causing intellectual deficits is striking. In addition to the many X-linked variants whose phenotypes include intellectual disability, there are many disorders that are *specifically* associated with X-linked intellectual deficiency, both syndromic and nonsyndromic; these are listed in OMIM as XLID followed by a number from 1 to 107. These disorders map from the telomere of the short arm to the last band on the long arm of the X. Although the role of the gene whose variant leads to the disorder is not always well defined, the genes responsible for X-linked intellectual disability are involved in many pathways. It seems that intelligence is the sum total of how all our genes are functioning. Malfunctions of genes in many pathways can interfere with intellectual capabilities. Extreme skewing of X-inactivation is frequently seen with XLID variants that permit male survival, and the variant is always found on the inactive X in females; consequently, they have normal intellectual function. Apparently, such disease-producing variants are toxic for expressing cells.

SUMMARY {#Sec16}
=======

Being mosaic for the function of their X-linked genes generally ameliorates the expression of X-linked deleterious variants in females. X-inactivation provides the opportunity to share gene products. If this is not possible, then cell selection may eliminate variant cells. Many of these variants affect intellectual ability. Females usually manifest their X-linked pathologic variants, if both alleles are disease variants, or if males with the same pathogenic variants are lost in utero. X-inactivation provides an enormous advantage to females with deleterious X-linked variants, most often enabling them to avoid disease manifestations, including intellectual disability, that affect males. Fortunately, chance skewing that favors mutant alleles is relatively rare (5%) in survivors. The female advantage is reflected by the 20% greater death rate for males at every stage postimplantation, until the age of \>75 years, when more females die because there are fewer male survivors.^[@CR41]^

The females susceptible to X-linked diseases are those who have more than one copy of a pathologic variant, or a relevant second variant, or a variant in an essential gene that does not permit males to survive (Table [2](#Tab2){ref-type="table"}). Females are also susceptible to chance skewing favoring the mutant allele, or the effects of X chromosomal aberrations (i.e., translocations) and monozygotic twinning on inducing unfavorable skewing.^[@CR42]^

The fact that more males are born than females (1.05:1) is also likely to be attributable to X-inactivation. In this case, preimplantation females are lost because of their greater dosage sensitivity in *maintaining* an active X.^[@CR11]^ But if XX individuals successfully establish X-inactivation while in utero, then throughout their lifetime, they will benefit from the cellular mosaicism it produces.
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